We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abingdon Health Plc | LSE:ABDX | London | Ordinary Share | GB00BLF79J41 | ORD 0.025P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.00 | 10.50 | 11.50 | 11.00 | 11.00 | 11.00 | 22,890 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 4.05M | -3.45M | -0.0284 | -3.87 | 13.39M |
TIDMABDX
RNS Number : 0295R
Abingdon Health PLC
24 October 2023
Abingdon Health plc
("Abingdon" or "the Company")
Award of Options under LTIP
York, U.K. 24 October 2023: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces that, under the terms of the existing Long Term Incentive Plan established in December 2022 ("LTIP" or the "Plan"), the Company has awarded share options ("Options") over a total of 2,386,238 ordinary shares of 0.025 pence each ("Ordinary Shares") to certain directors and senior management, in order to incentivise and encourage retention in a manner that aligns with the interests of the Company's shareholders.
The Options are nil cost and will vest over a three-year vesting period. Vesting of the Options is conditional upon the business achieving certain challenging revenue, adj. EBITDA and total shareholder return criteria. The Options will become exercisable between 24 October 2026 and 24 October 2033.
The following directors and members of the senior management team (each a person discharging managerial responsibilities ("PDMR")) have been awarded options:
PDMR Role No. of new No. of existing Total number Options awarded Options under of Options under the the LTIP under the LTIP LTIP Chief Executive Chris Yates Officer 850,459 1,285,714 2,136,173 Chris Hand Non-Executive Chairman 283,486 428,571 712,057 Chief Operating Mark Jones Officer 401,376 600,000 1,001,376 Chief Technical Nina Garrett Officer 337,156 515,000 852,156 Candice Vendetuolli Head of QARA 183,486 285,714 469,200 Natalie Thrush Head of HR 68,807 90,000 158,807 Head of Sales & Liam Currivan Marketing 261,468 - 261,468
As a result of these changes, the Company now has outstanding options over 5,719,162 Ordinary Shares equal to approximately 4.7 per cent. of the Company's issued share capital.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/ Chris Yates, Chief Executive Officer Via Walbrook PR Chris Hand, Non-Executive Chairman Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000 Nominated Adviser) Peter Steel, Alex Bond, Jalini Kalaravy Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867 Alice Woodings 984 082 +44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract research (CRO) and contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."
The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes.
Abingdon Health's Abingdon Simply Test (TM) range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test (TM) ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com
Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Chris Yates Reason for the notification 2 a) Position/status Chief Executive Officer b) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor a) Name Abingdon Health plc b) LEI 213800XFI4WV3FBILO20 Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares of 0.025 pence each financial instrument, type of instrument Identification code GB00BLF79J41 b) Nature of the transaction Award of LTIP Options c) Price(s) and volume(s) Price(s) Volume(s) Nil-cost 850,459 d) Aggregated information N/A single transaction - Aggregated volume - Price e) Date of the transaction 23(rd) October 2023 f) Place of the transaction Outside a trading venue Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Dr Chris Hand Reason for the notification 2 a) Position/status Non-Executive Chairman b) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor a) Name Abingdon Health plc b) LEI 213800XFI4WV3FBILO20 Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares of 0.025 pence each financial instrument, type of instrument Identification code GB00BLF79J41 b) Nature of the transaction Award of LTIP Options c) Price(s) and volume(s) Price(s) Volume(s) Nil cost 283,486 d) Aggregated information N/A single transaction - Aggregated volume - Price e) Date of the transaction 23(rd) October 2023 f) Place of the transaction Outside a trading venue Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Mark Jones Reason for the notification 2 a) Position/status Chief Operating Officer b) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor a) Name Abingdon Health plc b) LEI 213800XFI4WV3FBILO20 Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares of 0.025 pence each financial instrument, type of instrument Identification code GB00BLF79J41 b) Nature of the transaction Award of LTIP Options c) Price(s) and volume(s) Price(s) Volume(s) Nil cost 401,376 d) Aggregated information N/A single transaction - Aggregated volume - Price e) Date of the transaction 23(rd) October 2023 f) Place of the transaction Outside a trading venue Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Nina Garrett Reason for the notification 2 a) Position/status Chief Technical Officer
b) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor a) Name Abingdon Health plc b) LEI 213800XFI4WV3FBILO20 Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares of 0.025 pence each financial instrument, type of instrument Identification code GB00BLF79J41 b) Nature of the transaction Award of LTIP Options c) Price(s) and volume(s) Price(s) Volume(s) Nil cost 337,156 d) Aggregated information N/A single transaction - Aggregated volume - Price e) Date of the transaction 23(rd) October 2023 f) Place of the transaction Outside a trading venue Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Candice Vendetuolli Reason for the notification 2 a) Position/status Head of QARA b) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor a) Name Abingdon Health plc b) LEI 213800XFI4WV3FBILO20 Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares of 0.025 pence each financial instrument, type of instrument Identification code GB00BLF79J41 b) Nature of the transaction Award of LTIP Options c) Price(s) and volume(s) Price(s) Volume(s) Nil cost 183,486 d) Aggregated information N/A single transaction - Aggregated volume - Price e) Date of the transaction 23(rd) October 2023 f) Place of the transaction Outside a trading venue Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Natalie Thrush Reason for the notification 2 a) Position/status Head of HR b) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor a) Name Abingdon Health plc b) LEI 213800XFI4WV3FBILO20 Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares of 0.025 pence each financial instrument, type of instrument Identification code GB00BLF79J41 b) Nature of the transaction Award of LTIP Options c) Price(s) and volume(s) Price(s) Volume(s) Nil cost 68,807 d) Aggregated information N/A single transaction - Aggregated volume - Price e) Date of the transaction 23(rd) October 2023 f) Place of the transaction Outside a trading venue Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Liam Currivan Reason for the notification 2 a) Position/status Head of Sales & Marketing b) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor a) Name Abingdon Health plc b) LEI 213800XFI4WV3FBILO20 Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares of 0.025 pence each financial instrument, type of instrument Identification code GB00BLF79J41 b) Nature of the transaction Award of LTIP Options c) Price(s) and volume(s) Price(s) Volume(s) Nil cost 261,468 d) Aggregated information N/A single transaction - Aggregated volume - Price e) Date of the transaction 23(rd) October 2023 f) Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHMZMZGGFVGFZZ
(END) Dow Jones Newswires
October 24, 2023 02:05 ET (06:05 GMT)
1 Year Abingdon Health Chart |
1 Month Abingdon Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions